Bicycle Therapeutics PLC has a consensus price target of $42.88, established from looking at the 56 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, HC Wainwright & Co., and Needham on February 21, 2024. With an average price target of $52.67 between Canaccord Genuity, HC Wainwright & Co., and Needham, there's an implied 111.51% upside for Bicycle Therapeutics PLC from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/21/2024 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 140.96% | Canaccord Genuity | Bill Maughan | → $60 | Reiterates | Buy → Buy | Get Alert |
02/21/2024 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 120.88% | HC Wainwright & Co. | Swayampakula Ramakanth | $57 → $55 | Maintains | Buy | Get Alert |
02/21/2024 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 72.69% | Needham | Ami Fadia | → $43 | Reiterates | Buy → Buy | Get Alert |
12/20/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 28.51% | JMP Securities | Reni Benjamin | $44 → $32 | Maintains | Market Outperform | Get Alert |
12/15/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 72.69% | Needham | Ami Fadia | $46 → $43 | Maintains | Buy | Get Alert |
11/08/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 161.04% | Cantor Fitzgerald | Li Watsek | → $65 | Reiterates | Overweight → Overweight | Get Alert |
11/03/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 60.64% | Morgan Stanley | Jeffrey Hung | $42 → $40 | Maintains | Equal-Weight | Get Alert |
09/12/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 32.53% | B. Riley Securities | Kalpit Patel | → $33 | Upgrade | Neutral → Buy | Get Alert |
09/12/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 161.04% | Cantor Fitzgerald | Li Watsek | → $65 | Reiterates | Overweight → Overweight | Get Alert |
09/12/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 76.71% | JMP Securities | Reni Benjamin | → $44 | Reiterates | Market Outperform → Market Outperform | Get Alert |
09/12/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 84.74% | Needham | Ami Fadia | → $46 | Reiterates | Buy → Buy | Get Alert |
09/11/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 32.53% | B. Riley Securities | Kalpit Patel | $33 → $33 | Upgrade | Neutral → Buy | Get Alert |
09/07/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 161.04% | Cantor Fitzgerald | Li Watsek | → $65 | Reiterates | Overweight → Overweight | Get Alert |
08/04/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 68.67% | Morgan Stanley | Jeffrey Hung | $42 → $42 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
08/04/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 76.71% | JMP Securities | Reni Benjamin | $46 → $44 | Maintains | Outperform | Get Alert |
08/04/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 128.92% | HC Wainwright & Co. | Swayampakula Ramakanth | → $57 | Reiterates | Buy → Buy | Get Alert |
08/04/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 84.74% | Needham | Ami Fadia | $48 → $46 | Maintains | Buy | Get Alert |
08/03/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 100.8% | EF Hutton | Tony Butler | → $50 | Reiterates | → Buy | Get Alert |
05/11/2023 | BCYC | Buy Now | Bicycle Therapeutics | $24.90 | 84.74% | JMP Securities | Reni Benjamin | $46 → $46 | Reiterates | Market Outperform → Market Outperform | Get Alert |
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by Canaccord Genuity on February 21, 2024. The analyst firm set a price target for $60.00 expecting BCYC to rise to within 12 months (a possible 140.96% upside). 25 analyst firms have reported ratings in the last year.
The latest analyst rating for Bicycle Therapeutics (NASDAQ: BCYC) was provided by Canaccord Genuity, and Bicycle Therapeutics reiterated their buy rating.
The last upgrade for Bicycle Therapeutics PLC happened on September 12, 2023 when B. Riley Securities raised their price target to $33. B. Riley Securities previously had a neutral for Bicycle Therapeutics PLC.
The last downgrade for Bicycle Therapeutics PLC happened on April 13, 2022 when B. Riley Securities changed their price target from $62 to $33 for Bicycle Therapeutics PLC.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bicycle Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bicycle Therapeutics was filed on February 21, 2024 so you should expect the next rating to be made available sometime around February 21, 2025.
While ratings are subjective and will change, the latest Bicycle Therapeutics (BCYC) rating was a reiterated with a price target of $0.00 to $60.00. The current price Bicycle Therapeutics (BCYC) is trading at is $24.90, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.